Skye Bioscience, Inc. (SKYE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Skye Bioscience, Inc. (SKYE) closed at USD 1.57 on 2026-10-14, a change of -87.4 % over the past year, with a market capitalization of USD 7.04M.

Skye Bioscience, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Skye Bioscience, Inc. key figures

Previous close

USD 1.57 (2026-10-14)

1-year change

-87.4 %

Market cap

USD 7.04M

Enterprise value

USD -2.85M

P/E ratio (trailing)

-0.16

P/E ratio (forward)

-0.22

EPS (trailing)

-10.26

EPS (forward)

-7.40

PEG ratio

n/a

Price to book

-14.07

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.72

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Skye Bioscience, Inc. and compare it with other stocks.